SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech vs. Shorts
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (316)1/14/2000 11:15:00 AM
From: Neuroguy  Read Replies (2) of 427
 
Peter - emotive valuations of CLPA aside, it still falls into a category of a pretty classic short squeeze. A lot of big money is lined up to buy upon FDA approval, and when the price hits $20, the market cap reaches the magic $500M number. Both events will make it a potential buying target for various funds.

I can confirm KewlHand's estimate of late jan/early Feb for approval, but my crystal ball is a tad dusty as regards price predictions. A major fund manager quoted $50-70 by the summer, and $100-150 in a year. No idea where he derived those estimates from. $20-30 over the next month is certainly expected.

Are you still in SEPR? It's doing very nicely of late.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News